Companies / Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc.
RUBYCIK 1709401
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 19, 2021 | Flagship Ventures Fund IV General Partner LLC 10% owner | Buy Open-market buy | Common Stock | $2.03M | +70K +2.73% | 2,633,703 | high |
| Mar 19, 2021 | Flagship Ventures Fund IV General Partner LLC 10% owner | Buy Open-market buy | Common Stock | $2.03M | +70K +1.21% | 5,859,414 | high |
| Mar 19, 2021 | Flagship Ventures Fund IV General Partner LLC 10% owner | Buy Open-market buy | Common Stock | $2.03M | +70K +0.46% | 15,393,593 | high |
| Feb 8, 2021 | Epstein David R Director | Sell Open-market sale | Common Stock | $1.33M | -89K -1.85% | 4,726,220 | medium |
| Mar 15, 2021 | Keson-Brookes Maiken Executive | Sell Open-market sale | Common Stock | $506.0K | -25K -100.00% | 0 | medium |
| Feb 11, 2021 | Epstein David R Director | Sell Open-market sale | Common Stock | $398.6K | -27K -0.57% | 4,690,012 | medium |
| Mar 15, 2021 | Keson-Brookes Maiken Executive | Exercise Option exercise | Common Stock | $192.5K | +25K | 25,000 | low |
| Feb 10, 2021 | Epstein David R Director | Sell Open-market sale | Common Stock | $109.5K | -7K -0.16% | 4,716,716 | medium |